Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Idiopathic Pulmonary Fibrosis (IPF) – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
This ‘Idiopathic Pulmonary Fibrosis (IPF)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Idiopathic Pulmonary Fibrosis Epidemiology
The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries.
The epidemiology data for Idiopathic Pulmonary Fibrosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Idiopathic Pulmonary Fibrosis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to the publisher, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017.
Report Scope
- The report covers detailed overview of Idiopathic Pulmonary Fibrosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The report provides the insight about the historical and forecasted patient pool of Idiopathic Pulmonary Fibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
- The Report assesses the disease risk and burden and highlights the unmet needs of the disease
- The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report provides the segmentation of the disease epidemiology by Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of Idiopathic Pulmonary Fibrosis in 7MM
Key strengths
- 11 Year Forecast of Idiopathic Pulmonary Fibrosis epidemiology
- 7MM Coverage
- Total prevalent cases of IPF
- Incident Cases according to segmentation: Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF
Key Assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Key Topics Covered:
1. Key Insights
2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017
2.2. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2028
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Statistics about Idiopathic Pulmonary Fibrosis
3.3. Staging of Idiopathic Pulmonary Fibrosis
3.4. Risk Factors and Disease Causes
3.5. Symptoms
3.6. Pathogenesis
3.7. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
5. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
5.1. United States
5.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
5.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2. EU5
5.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. United Kingdom
5.2.6. Spain
5.3. Japan
6. Current Treatment Practices
6.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
6.2. Patient Journey
7. Unmet Needs
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/bted9b
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
